Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160702 | 0.85 | PRMT5 (0.42) | PRMT5TLR8TLR7LMNAHRH4 | |
| SCHEMBL2750294 | 0.76 | TLR8 (0.37) | PRMT5TLR8TLR7LMNAHRH4 | |
| SCHEMBL191231 | 0.76 | PRMT5 (0.44) | PRMT5TLR8TLR7LMNAHRH4 | |
| SCHEMBL4376577 | 0.73 | EGFR (0.42) | PRMT5HRH4 | |
| SCHEMBL5794472 | 0.72 | PRMT5 (0.40) | PRMT5TLR8TLR7LMNAHRH4 | |
| SCHEMBL6053091 | 0.69 | TLR8 (0.38) | PRMT5TLR8TLR7LMNAHRH4 | |
| SCHEMBL3354950 | 0.69 | TLR8 (0.38) | PRMT5TLR8TLR7LMNAHRH4 | |
| SCHEMBL3351060 | 0.69 | TLR8 (0.44) | PRMT5TLR8TLR7 | |
| SCHEMBL5618090 | 0.67 | TLR8 (0.39) | PRMT5TLR8TLR7LMNAHRH4 | |
| SCHEMBL4374283 | 0.67 | DHFR (0.39) | PRMT5TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939526-B2 | Sulfone substituted imidazo ring ethers | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-10 | — | — | US | disclosed |
| US-20070155767-A1 | Sulfone substituted imidazo ring ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-05 | — | — | US | disclosed |
| EP-1694674-A2 | SULFONE SUBSTITUTED IMIDAZO RING ETHERS | 3M Innovative Properties Company (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005076783-A2 | SULFONE SUBSTITUTED IMIDAZO RING ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155767-A1 | Sulfone substituted imidazo ring ethers | IL2, IL4, IFNG | PRMT5 1579/4885TLR8 145/4885TLR7 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.